-
Je něco špatně v tomto záznamu ?
Effectiveness of alcohol septal ablation for hypertrophic obstructive cardiomyopathy in patients with late gadolinium enhancement on cardiac magnetic resonance
E. Polaková, M. Liebregts, N. Marková, T. Adla, B. Kara, J. Ten Berg, J. Bonaventura, J. Veselka
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, pozorovací studie
- MeSH
- gadolinium * MeSH
- hypertrofická kardiomyopatie * diagnostické zobrazování chirurgie MeSH
- kontrastní látky MeSH
- lidé MeSH
- magnetická rezonanční tomografie MeSH
- retrospektivní studie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
BACKGROUND: According to European guidelines, alcohol septal ablation (ASA) for hypertrophic obstructive cardiomyopathy (HOCM) may be less effective in patients with extensive septal scarring on cardiac magnetic resonance (CMR). This study aimed to analyze the impact of late gadolinium enhancement (LGE) on CMR on the effectiveness of ASA. METHOD: We conducted an observational retrospective study involving adult patients with symptomatic drug-refractory HOCM who underwent CMR before ASA at two European centres from May 2010 through June 2019. Patients were compared in binary format based on LGE presence. Moreover, a subanalysis focused on patients with septal fibrosis was performed. The effectiveness of ASA was evaluated by echocardiographic, ECG and clinical findings. RESULTS: Of the 113 study patients, 54 (48%) had LGE on CMR. The LGE quantification performed in 29 patients revealed septal fibrosis in 17. The mean follow-up was 4.4 ± 2.6 years. Baseline parameters were similar between groups except for basal septal thickness that was greater in LGE+ group (21.1 ± 3.9 mm for LGE+ vs. 19.2 ± 3.2 mm for LGE-: p = .005). ASA improved symptoms in all groups and reduced left ventricular outflow tract obstruction (LVOTO) (delta gradient reduction: LGE+: 62 ± 37.3%; septal LGE+: 75.6 ± 20.8%; LGE-: 72.5 ± 21.0%). However, 13% of the LGE+ and 2% of the LGE- group had residual LVOTO above 30 mmHg (p = .027). CONCLUSION: ASA was effective in all patients with HOCM, whether they had LGE on CMR or not and whether they had septal fibrosis or not.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21019827
- 003
- CZ-PrNML
- 005
- 20210830101428.0
- 007
- ta
- 008
- 210728s2020 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ijcard.2020.06.049 $2 doi
- 035 __
- $a (PubMed)32682963
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Polaková, Eva $u Department of Cardiology, Second Medical School, Charles University, Motol University Hospital, Prague, Czech Republic. Electronic address: eva.polakova@fnmotol.cz
- 245 10
- $a Effectiveness of alcohol septal ablation for hypertrophic obstructive cardiomyopathy in patients with late gadolinium enhancement on cardiac magnetic resonance / $c E. Polaková, M. Liebregts, N. Marková, T. Adla, B. Kara, J. Ten Berg, J. Bonaventura, J. Veselka
- 520 9_
- $a BACKGROUND: According to European guidelines, alcohol septal ablation (ASA) for hypertrophic obstructive cardiomyopathy (HOCM) may be less effective in patients with extensive septal scarring on cardiac magnetic resonance (CMR). This study aimed to analyze the impact of late gadolinium enhancement (LGE) on CMR on the effectiveness of ASA. METHOD: We conducted an observational retrospective study involving adult patients with symptomatic drug-refractory HOCM who underwent CMR before ASA at two European centres from May 2010 through June 2019. Patients were compared in binary format based on LGE presence. Moreover, a subanalysis focused on patients with septal fibrosis was performed. The effectiveness of ASA was evaluated by echocardiographic, ECG and clinical findings. RESULTS: Of the 113 study patients, 54 (48%) had LGE on CMR. The LGE quantification performed in 29 patients revealed septal fibrosis in 17. The mean follow-up was 4.4 ± 2.6 years. Baseline parameters were similar between groups except for basal septal thickness that was greater in LGE+ group (21.1 ± 3.9 mm for LGE+ vs. 19.2 ± 3.2 mm for LGE-: p = .005). ASA improved symptoms in all groups and reduced left ventricular outflow tract obstruction (LVOTO) (delta gradient reduction: LGE+: 62 ± 37.3%; septal LGE+: 75.6 ± 20.8%; LGE-: 72.5 ± 21.0%). However, 13% of the LGE+ and 2% of the LGE- group had residual LVOTO above 30 mmHg (p = .027). CONCLUSION: ASA was effective in all patients with HOCM, whether they had LGE on CMR or not and whether they had septal fibrosis or not.
- 650 12
- $a hypertrofická kardiomyopatie $x diagnostické zobrazování $x chirurgie $7 D002312
- 650 _2
- $a kontrastní látky $7 D003287
- 650 12
- $a gadolinium $7 D005682
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a magnetická rezonanční tomografie $7 D008279
- 650 _2
- $a retrospektivní studie $7 D012189
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Liebregts, Max $u Department of Cardiology, St.Antonius Hospital, Nieuwegein, the Netherlands
- 700 1_
- $a Marková, Natália $u Department of Radiology, Second Medical School, Charles University, Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Adla, Theodor $u Department of Radiology, Second Medical School, Charles University, Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Kara, Basak $u Department of Cardiology, St.Antonius Hospital, Nieuwegein, the Netherlands
- 700 1_
- $a Ten Berg, Jurriën $u Department of Cardiology, St.Antonius Hospital, Nieuwegein, the Netherlands
- 700 1_
- $a Bonaventura, Jiří $u Department of Cardiology, Second Medical School, Charles University, Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Veselka, Josef $u Department of Cardiology, Second Medical School, Charles University, Motol University Hospital, Prague, Czech Republic
- 773 0_
- $w MED00002299 $t International journal of cardiology $x 1874-1754 $g Roč. 319, č. - (2020), s. 101-105
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32682963 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830101428 $b ABA008
- 999 __
- $a ok $b bmc $g 1690602 $s 1140273
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 319 $c - $d 101-105 $e 20200717 $i 1874-1754 $m International journal of cardiology $n Int J Cardiol $x MED00002299
- LZP __
- $a Pubmed-20210728
